Tim Smith

1 week ago | hcplive.com | Tim Smith

A new network meta-analysis has produced evidence on the comparative efficacy of alopecia areata monotherapies with different regimens of 8 Janus Kinase (JAK) inhibitors as well as dupilumab and apremilast.1This meta-analysis was led by a team of investigators such as Aditya K. Gupta, MD, PhD, from the Division of Dermatology a the University of Toronto Department of Medicine.

1 week ago | hcplive.com | Tim Smith

An announcement has been released that the US Food and Drug Administration (FDA) granted interchangeable biosimilar status to CT-P17 (Yuflyma), also known as adalimumab-aaty, which was designed as a high-concentration (100 mg/mL), citrate-free formulation of adalimumab (Humira).1The April 15 announcement by Celltrion, Inc.

1 week ago | hcplive.com | Tim Smith

Although topical ruxolitinib is being increasingly implemented off-label for different inflammatory skin conditions, a new systematic review suggests that there is consistent evidence of efficacy primarily for lichenoid or granulomatous dermatoses and mixed results for other conditions like alopecia areata.1 This systematic review was authored by a team of investigators who sought to assess off-label ruxolitinib utilization, given that data on the drug’s off-label use had mostly been limited...

1 week ago | hcplive.com | Tim Smith

Low cumulative 5α-reductase inhibitors (5-ARIs) doses in individuals with benign prostatic hyperplasia (BPH) or androgenic alopecia are linked to an increased suicide risk and a diminished risk of cardiovascular mortality, new findings suggest, highlighting the importance of careful monitoring and consistent dosing.1 These findings were the conclusion of research led by Jinhyun Kim—from the Department of Preventive Medicine at Yonsei University College of Medicine in South Korea—who worked...

1 week ago | hcplive.com | Tim Smith

New findings from a subgroup analysis show that adolescents with moderate-to-severe plaque psoriasis given with once-daily icotrokinra (JNJ-2113) attained higher rates of clear or almost clear skin at the 16-week mark versus those given a placebo and that there were no new safety signals.1,2 These data, announced on April 10 by Johnson & Johnson, resulted from the ICONIC-LEADa study, the first ever phase 3 registrational analysis of moderate-to-severe plaque psoriasis to evaluate the safety...